HPTN 083
From Wikipedia, the free encyclopedia
| full name | Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men |
|---|---|
| other names | CT02720094 |
| sponsor | ViiV Healthcare, Gilead Sciences[1] |
| number of participants | 4500[1] |
| start | 20 December 2016[2] |
| primary completion | June 2020[1] |
HPTN 083 is a 2016 clinical trial which compares cabotegravir injections with oral use of Emtricitabine/tenofovir as pre-exposure prophylaxis ("PrEP") for prevention of HIV/AIDS.
The study seeks to test injectable PrEP as a way to remedy adherence for many patients on a daily pill regimen.[3]
HPTN 083 is the first large scale phase III clinical trial of cabotegravir.[4]
In February 2016 researchers presented the results of the ECLAIR study.[5] That study examined cabotegravir and found no serious safety concerns.[5]
The research is a collaboration of Gilead Sciences, HIV Prevention Trials Network, ViiV Healthcare, National Institute of Allergy and Infectious Diseases.[6]
Local study sites will include John H. Stroger Jr. Hospital of Cook County.[7]
On May 18, 2020, HPTN announced that the long-acting injections had been found to be a highly effective treatment.[8]